Blonanserin: a review of its use in the management of schizophrenia.
Article Details
- CitationCopy to clipboard
Deeks ED, Keating GM
Blonanserin: a review of its use in the management of schizophrenia.
CNS Drugs. 2010 Jan;24(1):65-84. doi: 10.2165/11202620-000000000-00000.
- PubMed ID
- 20030420 [ View in PubMed]
- Abstract
Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomized and noncomparative trials. Notably, in two randomized, double-blind trials of 8 weeks' duration, blonanserin was noninferior to haloperidol or risperidone for primary endpoints, although it appeared to be better than haloperidol in improving negative symptoms. Blonanserin is generally well tolerated and appears to have an acceptable profile in terms of bodyweight gain. Potential tolerability benefits of the drug in short-term trials included fewer extrapyramidal symptoms than haloperidol and fewer reports of prolactin level increases or hyperprolactinaemia than risperidone. Nevertheless, extrapyramidal symptoms and hyperprolactinaemia were among the most common adverse reactions associated with blonanserin in noncomparative long-term studies. Further prospective and long-term comparative studies are required in order to definitively position blonanserin with respect to other antipsychotic agents. In the meantime, available clinical data suggest that blonanserin is an effective and generally well tolerated option for the short-term treatment of schizophrenia and for those requiring longer-term therapy.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Blonanserin 5-hydroxytryptamine receptor 2A Protein Humans YesAntagonistDetails Blonanserin Dopamine D2 receptor Protein Humans YesAntagonistDetails Blonanserin Dopamine D3 receptor Protein Humans YesAntagonistDetails - Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Blonanserin Cytochrome P450 3A4 Protein Humans NoSubstrateDetails - Drug Carriers
Drug Carrier Kind Organism Pharmacological Action Actions Blonanserin Serum albumin Protein Humans NoSubstrateDetails - Drug Reactions
Reaction Details Details Details Details Details Details
